nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—KIT—myenteric nerve plexus—Crohn's disease	0.0143	0.058	CbGeAlD
Nilotinib—PDGFRA—penis—Crohn's disease	0.0101	0.0411	CbGeAlD
Nilotinib—MAPK8—mouth—Crohn's disease	0.00586	0.0238	CbGeAlD
Nilotinib—CA9—gall bladder—Crohn's disease	0.00429	0.0174	CbGeAlD
Nilotinib—CA6—mouth—Crohn's disease	0.00421	0.0171	CbGeAlD
Nilotinib—EPHA4—mouth—Crohn's disease	0.00403	0.0164	CbGeAlD
Nilotinib—CA3—mouth—Crohn's disease	0.00398	0.0162	CbGeAlD
Nilotinib—MAPK14—mouth—Crohn's disease	0.00372	0.0151	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—Crohn's disease	0.00363	0.0147	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—Crohn's disease	0.00358	1	CbGdCrCtD
Nilotinib—FRK—lymphoid tissue—Crohn's disease	0.00344	0.014	CbGeAlD
Nilotinib—PDGFRA—gall bladder—Crohn's disease	0.00344	0.0139	CbGeAlD
Nilotinib—MAPK8—epithelium—Crohn's disease	0.00341	0.0138	CbGeAlD
Nilotinib—BLK—lymphoid tissue—Crohn's disease	0.00332	0.0135	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—Crohn's disease	0.00328	0.0133	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—Crohn's disease	0.00328	0.0133	CbGeAlD
Nilotinib—EPHB2—digestive system—Crohn's disease	0.00324	0.0132	CbGeAlD
Nilotinib—MAPK8—skin of body—Crohn's disease	0.00324	0.0131	CbGeAlD
Nilotinib—TIE1—epithelium—Crohn's disease	0.00295	0.012	CbGeAlD
Nilotinib—CDC42BPB—digestive system—Crohn's disease	0.00287	0.0116	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—Crohn's disease	0.00285	0.0115	CbGeAlD
Nilotinib—KIT—gall bladder—Crohn's disease	0.00275	0.0112	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—Crohn's disease	0.00269	0.0109	CbGeAlD
Nilotinib—PDGFRB—gall bladder—Crohn's disease	0.00268	0.0109	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—Crohn's disease	0.00262	0.0106	CbGeAlD
Nilotinib—MAPK8—digestive system—Crohn's disease	0.00259	0.0105	CbGeAlD
Nilotinib—KIT—mouth—Crohn's disease	0.00244	0.00992	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—Crohn's disease	0.00244	0.00989	CbGeAlD
Nilotinib—LYN—lymphoid tissue—Crohn's disease	0.00242	0.00983	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—Crohn's disease	0.00238	0.00968	CbGeAlD
Nilotinib—HCK—mammalian vulva—Crohn's disease	0.00224	0.00909	CbGeAlD
Nilotinib—MAPK14—epithelium—Crohn's disease	0.00216	0.00878	CbGeAlD
Nilotinib—EPHB3—digestive system—Crohn's disease	0.00214	0.00867	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—Crohn's disease	0.00208	0.00846	CbGeAlD
Nilotinib—MAPK14—skin of body—Crohn's disease	0.00206	0.00835	CbGeAlD
Nilotinib—EPHB4—epithelium—Crohn's disease	0.00205	0.00832	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—Crohn's disease	0.00204	0.00826	CbGeAlD
Nilotinib—EPHA2—epithelium—Crohn's disease	0.00201	0.00816	CbGeAlD
Nilotinib—HCK—lymphoid tissue—Crohn's disease	0.00199	0.00807	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—Crohn's disease	0.00198	0.00802	CbGeAlD
Nilotinib—HCK—digestive system—Crohn's disease	0.00196	0.00797	CbGeAlD
Nilotinib—TEK—epithelium—Crohn's disease	0.00196	0.00797	CbGeAlD
Nilotinib—CA7—digestive system—Crohn's disease	0.00192	0.0078	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—Crohn's disease	0.00189	0.00767	CbGeAlD
Nilotinib—BLK—lymph node—Crohn's disease	0.00187	0.0076	CbGeAlD
Nilotinib—FGR—mammalian vulva—Crohn's disease	0.00187	0.00758	CbGeAlD
Nilotinib—LCK—mammalian vulva—Crohn's disease	0.00187	0.00758	CbGeAlD
Nilotinib—EPHB6—skin of body—Crohn's disease	0.00178	0.00724	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—Crohn's disease	0.00178	0.00722	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—Crohn's disease	0.00175	0.00708	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—Crohn's disease	0.00171	0.00695	CbGeAlD
Nilotinib—CA9—digestive system—Crohn's disease	0.00169	0.00685	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—Crohn's disease	0.00167	0.00676	CbGeAlD
Nilotinib—FGR—lymphoid tissue—Crohn's disease	0.00166	0.00673	CbGeAlD
Nilotinib—MAPK11—lymph node—Crohn's disease	0.00165	0.0067	CbGeAlD
Nilotinib—MAPK14—digestive system—Crohn's disease	0.00165	0.00668	CbGeAlD
Nilotinib—FGR—digestive system—Crohn's disease	0.00164	0.00665	CbGeAlD
Nilotinib—CDC42BPB—lymph node—Crohn's disease	0.00164	0.00664	CbGeAlD
Nilotinib—CA2—gall bladder—Crohn's disease	0.00163	0.00661	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—Crohn's disease	0.00163	0.0066	CbGeAlD
Nilotinib—EPHB4—digestive system—Crohn's disease	0.00156	0.00633	CbGeAlD
Nilotinib—EPHA3—lymph node—Crohn's disease	0.00155	0.0063	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—Crohn's disease	0.00155	0.00629	CbGeAlD
Nilotinib—EPHA2—digestive system—Crohn's disease	0.00153	0.00621	CbGeAlD
Nilotinib—TEK—lymphoid tissue—Crohn's disease	0.00151	0.00613	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—Crohn's disease	0.00151	0.00612	CbGeAlD
Nilotinib—CSF1R—skin of body—Crohn's disease	0.00149	0.00604	CbGeAlD
Nilotinib—MAPK8—lymph node—Crohn's disease	0.00148	0.00601	CbGeAlD
Nilotinib—CA2—mouth—Crohn's disease	0.00145	0.00588	CbGeAlD
Nilotinib—KIT—epithelium—Crohn's disease	0.00142	0.00577	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—Crohn's disease	0.00139	0.00565	CbGeAlD
Nilotinib—PDGFRB—epithelium—Crohn's disease	0.00139	0.00563	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—Crohn's disease	0.00137	0.00556	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—Crohn's disease	0.00137	0.00556	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—Crohn's disease	0.00136	0.00551	CbGeAlD
Nilotinib—PDGFRA—digestive system—Crohn's disease	0.00135	0.00549	CbGeAlD
Nilotinib—KIT—skin of body—Crohn's disease	0.00135	0.00549	CbGeAlD
Nilotinib—MAP4K1—lymph node—Crohn's disease	0.00135	0.00546	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—Crohn's disease	0.00134	0.00543	CbGeAlD
Nilotinib—PDGFRB—skin of body—Crohn's disease	0.00132	0.00536	CbGeAlD
Nilotinib—UGT1A1—digestive system—Crohn's disease	0.00129	0.00524	CbGeAlD
Nilotinib—TIE1—lymph node—Crohn's disease	0.00128	0.00521	CbGeAlD
Nilotinib—CA12—digestive system—Crohn's disease	0.00125	0.00507	CbGeAlD
Nilotinib—KIT—mammalian vulva—Crohn's disease	0.00123	0.005	CbGeAlD
Nilotinib—BRAF—lymph node—Crohn's disease	0.00123	0.00499	CbGeAlD
Nilotinib—EPHB3—lymph node—Crohn's disease	0.00122	0.00495	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—Crohn's disease	0.00121	0.00489	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—Crohn's disease	0.0012	0.00489	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—Crohn's disease	0.00119	0.00484	CbGeAlD
Nilotinib—CSF1R—digestive system—Crohn's disease	0.00119	0.00483	CbGeAlD
Nilotinib—ABL1—skin of body—Crohn's disease	0.00118	0.00478	CbGeAlD
Nilotinib—HCK—lymph node—Crohn's disease	0.00112	0.00455	CbGeAlD
Nilotinib—ABL2—lymph node—Crohn's disease	0.00112	0.00452	CbGeAlD
Nilotinib—KIT—lymphoid tissue—Crohn's disease	0.0011	0.00444	CbGeAlD
Nilotinib—KIT—digestive system—Crohn's disease	0.00108	0.00439	CbGeAlD
Nilotinib—ABL1—mammalian vulva—Crohn's disease	0.00107	0.00436	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—Crohn's disease	0.00107	0.00434	CbGeAlD
Nilotinib—PDGFRB—digestive system—Crohn's disease	0.00106	0.00429	CbGeAlD
Nilotinib—EPHA4—lymph node—Crohn's disease	0.00102	0.00414	CbGeAlD
Nilotinib—CA3—lymph node—Crohn's disease	0.00101	0.00409	CbGeAlD
Nilotinib—CA1—lymphoid tissue—Crohn's disease	0.001	0.00406	CbGeAlD
Nilotinib—CA1—digestive system—Crohn's disease	0.000989	0.00401	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—Crohn's disease	0.000953	0.00387	CbGeAlD
Nilotinib—ABL1—digestive system—Crohn's disease	0.000942	0.00382	CbGeAlD
Nilotinib—MAPK14—lymph node—Crohn's disease	0.00094	0.00382	CbGeAlD
Nilotinib—FGR—lymph node—Crohn's disease	0.000936	0.0038	CbGeAlD
Nilotinib—LCK—lymph node—Crohn's disease	0.000936	0.0038	CbGeAlD
Nilotinib—EPHB4—lymph node—Crohn's disease	0.000891	0.00362	CbGeAlD
Nilotinib—EPHA2—lymph node—Crohn's disease	0.000874	0.00355	CbGeAlD
Nilotinib—TEK—lymph node—Crohn's disease	0.000853	0.00346	CbGeAlD
Nilotinib—CA2—epithelium—Crohn's disease	0.000843	0.00342	CbGeAlD
Nilotinib—EPHB6—lymph node—Crohn's disease	0.000815	0.00331	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—Crohn's disease	0.000812	0.00329	CbGeAlD
Nilotinib—CA2—skin of body—Crohn's disease	0.000802	0.00325	CbGeAlD
Nilotinib—Breast disorder—Mesalazine—Crohn's disease	0.000778	0.00228	CcSEcCtD
Nilotinib—Pancytopenia—Azathioprine—Crohn's disease	0.000776	0.00227	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.000775	0.00227	CcSEcCtD
Nilotinib—CA4—digestive system—Crohn's disease	0.000773	0.00314	CbGeAlD
Nilotinib—PDGFRA—lymph node—Crohn's disease	0.000773	0.00314	CbGeAlD
Nilotinib—Nasopharyngitis—Mesalazine—Crohn's disease	0.00077	0.00225	CcSEcCtD
Nilotinib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000763	0.00224	CcSEcCtD
Nilotinib—Petechiae—Prednisone—Crohn's disease	0.000763	0.00223	CcSEcCtD
Nilotinib—Gastritis—Mesalazine—Crohn's disease	0.000762	0.00223	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000759	0.00222	CcSEcCtD
Nilotinib—Skin disorder—Mercaptopurine—Crohn's disease	0.000757	0.00222	CcSEcCtD
Nilotinib—Endocrine disorder—Prednisone—Crohn's disease	0.000757	0.00222	CcSEcCtD
Nilotinib—Abdominal distension—Mesalazine—Crohn's disease	0.000749	0.00219	CcSEcCtD
Nilotinib—Influenza—Mesalazine—Crohn's disease	0.000744	0.00218	CcSEcCtD
Nilotinib—Anorexia—Mercaptopurine—Crohn's disease	0.000743	0.00218	CcSEcCtD
Nilotinib—Eosinophilia—Mesalazine—Crohn's disease	0.000737	0.00216	CcSEcCtD
Nilotinib—Pneumonia—Azathioprine—Crohn's disease	0.000732	0.00215	CcSEcCtD
Nilotinib—CA2—mammalian vulva—Crohn's disease	0.000731	0.00297	CbGeAlD
Nilotinib—Pancreatitis—Mesalazine—Crohn's disease	0.000729	0.00214	CcSEcCtD
Nilotinib—Infestation NOS—Azathioprine—Crohn's disease	0.000728	0.00213	CcSEcCtD
Nilotinib—Infestation—Azathioprine—Crohn's disease	0.000728	0.00213	CcSEcCtD
Nilotinib—Angina pectoris—Mesalazine—Crohn's disease	0.000725	0.00212	CcSEcCtD
Nilotinib—Contusion—Prednisone—Crohn's disease	0.000719	0.00211	CcSEcCtD
Nilotinib—Bronchitis—Mesalazine—Crohn's disease	0.000715	0.0021	CcSEcCtD
Nilotinib—Abdominal discomfort—Mesalazine—Crohn's disease	0.000713	0.00209	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00071	0.00208	CcSEcCtD
Nilotinib—Pancytopenia—Mesalazine—Crohn's disease	0.000706	0.00207	CcSEcCtD
Nilotinib—MAP2K5—lymph node—Crohn's disease	0.000697	0.00283	CbGeAlD
Nilotinib—Dysuria—Mesalazine—Crohn's disease	0.000696	0.00204	CcSEcCtD
Nilotinib—Neutropenia—Mesalazine—Crohn's disease	0.000696	0.00204	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000691	0.00203	CcSEcCtD
Nilotinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000689	0.00202	CcSEcCtD
Nilotinib—Pollakiuria—Mesalazine—Crohn's disease	0.000687	0.00201	CcSEcCtD
Nilotinib—CYP2B6—skin of body—Crohn's disease	0.000685	0.00278	CbGeAlD
Nilotinib—CSF1R—lymph node—Crohn's disease	0.00068	0.00276	CbGeAlD
Nilotinib—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000679	0.00199	CcSEcCtD
Nilotinib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000678	0.00199	CcSEcCtD
Nilotinib—ABCG2—mammalian vulva—Crohn's disease	0.000677	0.00275	CbGeAlD
Nilotinib—Weight increased—Mesalazine—Crohn's disease	0.000677	0.00198	CcSEcCtD
Nilotinib—Weight decreased—Mesalazine—Crohn's disease	0.000673	0.00197	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000673	0.00197	CcSEcCtD
Nilotinib—Leukocytosis—Prednisone—Crohn's disease	0.000668	0.00196	CcSEcCtD
Nilotinib—Pneumonia—Mesalazine—Crohn's disease	0.000667	0.00195	CcSEcCtD
Nilotinib—Infestation NOS—Mesalazine—Crohn's disease	0.000663	0.00194	CcSEcCtD
Nilotinib—Infestation—Mesalazine—Crohn's disease	0.000663	0.00194	CcSEcCtD
Nilotinib—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000663	0.00194	CcSEcCtD
Nilotinib—Haemoglobin—Azathioprine—Crohn's disease	0.000657	0.00192	CcSEcCtD
Nilotinib—Haemorrhage—Azathioprine—Crohn's disease	0.000654	0.00192	CcSEcCtD
Nilotinib—Renal failure—Mesalazine—Crohn's disease	0.000652	0.00191	CcSEcCtD
Nilotinib—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00065	0.0019	CcSEcCtD
Nilotinib—CA2—lymphoid tissue—Crohn's disease	0.000649	0.00263	CbGeAlD
Nilotinib—Jaundice—Mesalazine—Crohn's disease	0.000647	0.00189	CcSEcCtD
Nilotinib—Stomatitis—Mesalazine—Crohn's disease	0.000647	0.00189	CcSEcCtD
Nilotinib—Conjunctivitis—Mesalazine—Crohn's disease	0.000645	0.00189	CcSEcCtD
Nilotinib—Urinary tract infection—Mesalazine—Crohn's disease	0.000645	0.00189	CcSEcCtD
Nilotinib—CA2—digestive system—Crohn's disease	0.000641	0.0026	CbGeAlD
Nilotinib—Haematuria—Mesalazine—Crohn's disease	0.000632	0.00185	CcSEcCtD
Nilotinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000627	0.00184	CcSEcCtD
Nilotinib—Epistaxis—Mesalazine—Crohn's disease	0.000626	0.00183	CcSEcCtD
Nilotinib—Erythema multiforme—Azathioprine—Crohn's disease	0.000618	0.00181	CcSEcCtD
Nilotinib—KIT—lymph node—Crohn's disease	0.000618	0.00251	CbGeAlD
Nilotinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000616	0.00181	CcSEcCtD
Nilotinib—PDGFRB—lymph node—Crohn's disease	0.000603	0.00245	CbGeAlD
Nilotinib—Skin exfoliation—Prednisone—Crohn's disease	0.000599	0.00175	CcSEcCtD
Nilotinib—Haemoglobin—Mesalazine—Crohn's disease	0.000598	0.00175	CcSEcCtD
Nilotinib—Rhinitis—Mesalazine—Crohn's disease	0.000597	0.00175	CcSEcCtD
Nilotinib—Fluid retention—Prednisone—Crohn's disease	0.000596	0.00174	CcSEcCtD
Nilotinib—Haemorrhage—Mesalazine—Crohn's disease	0.000595	0.00174	CcSEcCtD
Nilotinib—Hepatitis—Mesalazine—Crohn's disease	0.000595	0.00174	CcSEcCtD
Nilotinib—Pharyngitis—Mesalazine—Crohn's disease	0.000591	0.00173	CcSEcCtD
Nilotinib—Immune system disorder—Azathioprine—Crohn's disease	0.00059	0.00173	CcSEcCtD
Nilotinib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000589	0.00173	CcSEcCtD
Nilotinib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000588	0.00172	CcSEcCtD
Nilotinib—Oedema peripheral—Mesalazine—Crohn's disease	0.000587	0.00172	CcSEcCtD
Nilotinib—Chills—Azathioprine—Crohn's disease	0.000587	0.00172	CcSEcCtD
Nilotinib—Connective tissue disorder—Mesalazine—Crohn's disease	0.000585	0.00171	CcSEcCtD
Nilotinib—Arrhythmia—Azathioprine—Crohn's disease	0.000584	0.00171	CcSEcCtD
Nilotinib—Urethral disorder—Mesalazine—Crohn's disease	0.000584	0.00171	CcSEcCtD
Nilotinib—Alopecia—Azathioprine—Crohn's disease	0.000578	0.00169	CcSEcCtD
Nilotinib—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000574	0.00168	CcSEcCtD
Nilotinib—Ecchymosis—Prednisone—Crohn's disease	0.000567	0.00166	CcSEcCtD
Nilotinib—CA1—lymph node—Crohn's disease	0.000565	0.00229	CbGeAlD
Nilotinib—Erythema multiforme—Mesalazine—Crohn's disease	0.000563	0.00165	CcSEcCtD
Nilotinib—Pulmonary oedema—Prednisone—Crohn's disease	0.000558	0.00164	CcSEcCtD
Nilotinib—Eye disorder—Mesalazine—Crohn's disease	0.000556	0.00163	CcSEcCtD
Nilotinib—Tinnitus—Mesalazine—Crohn's disease	0.000555	0.00163	CcSEcCtD
Nilotinib—CYP2B6—lymphoid tissue—Crohn's disease	0.000555	0.00225	CbGeAlD
Nilotinib—Cardiac disorder—Mesalazine—Crohn's disease	0.000553	0.00162	CcSEcCtD
Nilotinib—CYP2B6—digestive system—Crohn's disease	0.000548	0.00222	CbGeAlD
Nilotinib—Sepsis—Prednisone—Crohn's disease	0.000544	0.00159	CcSEcCtD
Nilotinib—CYP2C9—digestive system—Crohn's disease	0.000542	0.0022	CbGeAlD
Nilotinib—Angiopathy—Mesalazine—Crohn's disease	0.00054	0.00158	CcSEcCtD
Nilotinib—ABL1—lymph node—Crohn's disease	0.000538	0.00218	CbGeAlD
Nilotinib—Immune system disorder—Mesalazine—Crohn's disease	0.000538	0.00158	CcSEcCtD
Nilotinib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000537	0.00157	CcSEcCtD
Nilotinib—Chills—Mesalazine—Crohn's disease	0.000534	0.00157	CcSEcCtD
Nilotinib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000533	0.00156	CcSEcCtD
Nilotinib—Ill-defined disorder—Azathioprine—Crohn's disease	0.000528	0.00155	CcSEcCtD
Nilotinib—Alopecia—Mesalazine—Crohn's disease	0.000526	0.00154	CcSEcCtD
Nilotinib—Anaemia—Azathioprine—Crohn's disease	0.000526	0.00154	CcSEcCtD
Nilotinib—Diabetes mellitus—Prednisone—Crohn's disease	0.000524	0.00153	CcSEcCtD
Nilotinib—Mental disorder—Mesalazine—Crohn's disease	0.000522	0.00153	CcSEcCtD
Nilotinib—Erythema—Mesalazine—Crohn's disease	0.000518	0.00152	CcSEcCtD
Nilotinib—Malaise—Azathioprine—Crohn's disease	0.000513	0.0015	CcSEcCtD
Nilotinib—Flatulence—Mesalazine—Crohn's disease	0.000511	0.0015	CcSEcCtD
Nilotinib—Leukopenia—Azathioprine—Crohn's disease	0.000509	0.00149	CcSEcCtD
Nilotinib—Dysgeusia—Mesalazine—Crohn's disease	0.000508	0.00149	CcSEcCtD
Nilotinib—Back pain—Mesalazine—Crohn's disease	0.000501	0.00147	CcSEcCtD
Nilotinib—Muscle spasms—Mesalazine—Crohn's disease	0.000498	0.00146	CcSEcCtD
Nilotinib—Vomiting—Mercaptopurine—Crohn's disease	0.000496	0.00145	CcSEcCtD
Nilotinib—Rash—Mercaptopurine—Crohn's disease	0.000491	0.00144	CcSEcCtD
Nilotinib—Dermatitis—Mercaptopurine—Crohn's disease	0.000491	0.00144	CcSEcCtD
Nilotinib—Vision blurred—Mesalazine—Crohn's disease	0.000489	0.00143	CcSEcCtD
Nilotinib—Tremor—Mesalazine—Crohn's disease	0.000486	0.00142	CcSEcCtD
Nilotinib—Increased appetite—Prednisone—Crohn's disease	0.000485	0.00142	CcSEcCtD
Nilotinib—Amnesia—Prednisone—Crohn's disease	0.000485	0.00142	CcSEcCtD
Nilotinib—Arthralgia—Azathioprine—Crohn's disease	0.000484	0.00142	CcSEcCtD
Nilotinib—Myalgia—Azathioprine—Crohn's disease	0.000484	0.00142	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000481	0.00141	CcSEcCtD
Nilotinib—Ill-defined disorder—Mesalazine—Crohn's disease	0.000481	0.00141	CcSEcCtD
Nilotinib—Anaemia—Mesalazine—Crohn's disease	0.000479	0.0014	CcSEcCtD
Nilotinib—Discomfort—Azathioprine—Crohn's disease	0.000479	0.0014	CcSEcCtD
Nilotinib—Malaise—Mesalazine—Crohn's disease	0.000467	0.00137	CcSEcCtD
Nilotinib—Cardiac failure—Prednisone—Crohn's disease	0.000467	0.00137	CcSEcCtD
Nilotinib—Vertigo—Mesalazine—Crohn's disease	0.000466	0.00136	CcSEcCtD
Nilotinib—Syncope—Mesalazine—Crohn's disease	0.000465	0.00136	CcSEcCtD
Nilotinib—Lethargy—Prednisone—Crohn's disease	0.000465	0.00136	CcSEcCtD
Nilotinib—Leukopenia—Mesalazine—Crohn's disease	0.000464	0.00136	CcSEcCtD
Nilotinib—Nausea—Mercaptopurine—Crohn's disease	0.000463	0.00136	CcSEcCtD
Nilotinib—Infection—Azathioprine—Crohn's disease	0.000461	0.00135	CcSEcCtD
Nilotinib—Palpitations—Mesalazine—Crohn's disease	0.000458	0.00134	CcSEcCtD
Nilotinib—Loss of consciousness—Mesalazine—Crohn's disease	0.000456	0.00133	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000455	0.00133	CcSEcCtD
Nilotinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000455	0.00133	CcSEcCtD
Nilotinib—Cough—Mesalazine—Crohn's disease	0.000452	0.00133	CcSEcCtD
Nilotinib—Skin disorder—Azathioprine—Crohn's disease	0.000451	0.00132	CcSEcCtD
Nilotinib—Hypertension—Mesalazine—Crohn's disease	0.000448	0.00131	CcSEcCtD
Nilotinib—CA4—lymph node—Crohn's disease	0.000442	0.00179	CbGeAlD
Nilotinib—Myalgia—Mesalazine—Crohn's disease	0.000441	0.00129	CcSEcCtD
Nilotinib—Arthralgia—Mesalazine—Crohn's disease	0.000441	0.00129	CcSEcCtD
Nilotinib—Chest pain—Mesalazine—Crohn's disease	0.000441	0.00129	CcSEcCtD
Nilotinib—Anxiety—Mesalazine—Crohn's disease	0.00044	0.00129	CcSEcCtD
Nilotinib—Face oedema—Prednisone—Crohn's disease	0.00044	0.00129	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000438	0.00128	CcSEcCtD
Nilotinib—Discomfort—Mesalazine—Crohn's disease	0.000436	0.00128	CcSEcCtD
Nilotinib—Hypotension—Azathioprine—Crohn's disease	0.000434	0.00127	CcSEcCtD
Nilotinib—Dry mouth—Mesalazine—Crohn's disease	0.000432	0.00126	CcSEcCtD
Nilotinib—Confusional state—Mesalazine—Crohn's disease	0.000427	0.00125	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000423	0.00124	CcSEcCtD
Nilotinib—Oedema—Mesalazine—Crohn's disease	0.000423	0.00124	CcSEcCtD
Nilotinib—Infection—Mesalazine—Crohn's disease	0.00042	0.00123	CcSEcCtD
Nilotinib—Dry skin—Prednisone—Crohn's disease	0.000417	0.00122	CcSEcCtD
Nilotinib—Shock—Mesalazine—Crohn's disease	0.000416	0.00122	CcSEcCtD
Nilotinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000415	0.00122	CcSEcCtD
Nilotinib—Hypokalaemia—Prednisone—Crohn's disease	0.000414	0.00121	CcSEcCtD
Nilotinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000414	0.00121	CcSEcCtD
Nilotinib—CYP3A4—digestive system—Crohn's disease	0.000414	0.00168	CbGeAlD
Nilotinib—Tachycardia—Mesalazine—Crohn's disease	0.000413	0.00121	CcSEcCtD
Nilotinib—Skin disorder—Mesalazine—Crohn's disease	0.000411	0.0012	CcSEcCtD
Nilotinib—Hyperhidrosis—Mesalazine—Crohn's disease	0.000409	0.0012	CcSEcCtD
Nilotinib—CYP2D6—digestive system—Crohn's disease	0.000407	0.00165	CbGeAlD
Nilotinib—Anorexia—Mesalazine—Crohn's disease	0.000403	0.00118	CcSEcCtD
Nilotinib—Muscular weakness—Prednisone—Crohn's disease	0.000402	0.00118	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000402	0.00118	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000401	0.00117	CcSEcCtD
Nilotinib—Abdominal distension—Prednisone—Crohn's disease	0.000396	0.00116	CcSEcCtD
Nilotinib—Hypotension—Mesalazine—Crohn's disease	0.000395	0.00116	CcSEcCtD
Nilotinib—Pancreatitis—Prednisone—Crohn's disease	0.000386	0.00113	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000385	0.00113	CcSEcCtD
Nilotinib—ABCB1—epithelium—Crohn's disease	0.000385	0.00156	CbGeAlD
Nilotinib—Feeling abnormal—Azathioprine—Crohn's disease	0.000383	0.00112	CcSEcCtD
Nilotinib—Insomnia—Mesalazine—Crohn's disease	0.000383	0.00112	CcSEcCtD
Nilotinib—Paraesthesia—Mesalazine—Crohn's disease	0.00038	0.00111	CcSEcCtD
Nilotinib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00038	0.00111	CcSEcCtD
Nilotinib—Dyspnoea—Mesalazine—Crohn's disease	0.000377	0.0011	CcSEcCtD
Nilotinib—Dyspepsia—Mesalazine—Crohn's disease	0.000372	0.00109	CcSEcCtD
Nilotinib—Neutropenia—Prednisone—Crohn's disease	0.000368	0.00108	CcSEcCtD
Nilotinib—Decreased appetite—Mesalazine—Crohn's disease	0.000368	0.00108	CcSEcCtD
Nilotinib—Abdominal pain—Azathioprine—Crohn's disease	0.000367	0.00108	CcSEcCtD
Nilotinib—Body temperature increased—Azathioprine—Crohn's disease	0.000367	0.00108	CcSEcCtD
Nilotinib—CA2—lymph node—Crohn's disease	0.000366	0.00149	CbGeAlD
Nilotinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000365	0.00107	CcSEcCtD
Nilotinib—Fatigue—Mesalazine—Crohn's disease	0.000365	0.00107	CcSEcCtD
Nilotinib—Erectile dysfunction—Prednisone—Crohn's disease	0.000363	0.00106	CcSEcCtD
Nilotinib—Pain—Mesalazine—Crohn's disease	0.000362	0.00106	CcSEcCtD
Nilotinib—Constipation—Mesalazine—Crohn's disease	0.000362	0.00106	CcSEcCtD
Nilotinib—Weight increased—Prednisone—Crohn's disease	0.000358	0.00105	CcSEcCtD
Nilotinib—Weight decreased—Prednisone—Crohn's disease	0.000356	0.00104	CcSEcCtD
Nilotinib—Hyperglycaemia—Prednisone—Crohn's disease	0.000355	0.00104	CcSEcCtD
Nilotinib—Feeling abnormal—Mesalazine—Crohn's disease	0.000349	0.00102	CcSEcCtD
Nilotinib—Acute coronary syndrome—Prednisone—Crohn's disease	0.000346	0.00101	CcSEcCtD
Nilotinib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000346	0.00101	CcSEcCtD
Nilotinib—Myocardial infarction—Prednisone—Crohn's disease	0.000344	0.00101	CcSEcCtD
Nilotinib—Neuropathy peripheral—Prednisone—Crohn's disease	0.000344	0.00101	CcSEcCtD
Nilotinib—Hypersensitivity—Azathioprine—Crohn's disease	0.000342	0.001	CcSEcCtD
Nilotinib—ABCG2—lymph node—Crohn's disease	0.000339	0.00138	CbGeAlD
Nilotinib—Urticaria—Mesalazine—Crohn's disease	0.000336	0.000985	CcSEcCtD
Nilotinib—Abdominal pain—Mesalazine—Crohn's disease	0.000334	0.00098	CcSEcCtD
Nilotinib—Body temperature increased—Mesalazine—Crohn's disease	0.000334	0.00098	CcSEcCtD
Nilotinib—ABCB1—mammalian vulva—Crohn's disease	0.000334	0.00135	CbGeAlD
Nilotinib—Bradycardia—Prednisone—Crohn's disease	0.000321	0.00094	CcSEcCtD
Nilotinib—Diarrhoea—Azathioprine—Crohn's disease	0.000318	0.000931	CcSEcCtD
Nilotinib—Haemoglobin—Prednisone—Crohn's disease	0.000317	0.000928	CcSEcCtD
Nilotinib—Haemorrhage—Prednisone—Crohn's disease	0.000315	0.000923	CcSEcCtD
Nilotinib—Hypersensitivity—Mesalazine—Crohn's disease	0.000312	0.000913	CcSEcCtD
Nilotinib—Connective tissue disorder—Prednisone—Crohn's disease	0.00031	0.000907	CcSEcCtD
Nilotinib—Dizziness—Azathioprine—Crohn's disease	0.000307	0.0009	CcSEcCtD
Nilotinib—Asthenia—Mesalazine—Crohn's disease	0.000304	0.000889	CcSEcCtD
Nilotinib—Pruritus—Mesalazine—Crohn's disease	0.000299	0.000877	CcSEcCtD
Nilotinib—ABCB1—lymphoid tissue—Crohn's disease	0.000296	0.0012	CbGeAlD
Nilotinib—Vomiting—Azathioprine—Crohn's disease	0.000295	0.000865	CcSEcCtD
Nilotinib—Eye disorder—Prednisone—Crohn's disease	0.000294	0.000863	CcSEcCtD
Nilotinib—Rash—Azathioprine—Crohn's disease	0.000293	0.000858	CcSEcCtD
Nilotinib—ABCB1—digestive system—Crohn's disease	0.000293	0.00119	CbGeAlD
Nilotinib—Dermatitis—Azathioprine—Crohn's disease	0.000293	0.000857	CcSEcCtD
Nilotinib—Flushing—Prednisone—Crohn's disease	0.000292	0.000857	CcSEcCtD
Nilotinib—Headache—Azathioprine—Crohn's disease	0.000291	0.000852	CcSEcCtD
Nilotinib—Diarrhoea—Mesalazine—Crohn's disease	0.000289	0.000848	CcSEcCtD
Nilotinib—Angiopathy—Prednisone—Crohn's disease	0.000286	0.000837	CcSEcCtD
Nilotinib—Immune system disorder—Prednisone—Crohn's disease	0.000285	0.000834	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—Crohn's disease	0.000281	0.000824	CcSEcCtD
Nilotinib—Dizziness—Mesalazine—Crohn's disease	0.00028	0.00082	CcSEcCtD
Nilotinib—Alopecia—Prednisone—Crohn's disease	0.000278	0.000816	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—Crohn's disease	0.000276	0.000809	CcSEcCtD
Nilotinib—Nausea—Azathioprine—Crohn's disease	0.000276	0.000808	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—Crohn's disease	0.000274	0.000803	CcSEcCtD
Nilotinib—Erythema—Prednisone—Crohn's disease	0.000274	0.000803	CcSEcCtD
Nilotinib—Vomiting—Mesalazine—Crohn's disease	0.000269	0.000788	CcSEcCtD
Nilotinib—Rash—Mesalazine—Crohn's disease	0.000267	0.000781	CcSEcCtD
Nilotinib—Dermatitis—Mesalazine—Crohn's disease	0.000266	0.000781	CcSEcCtD
Nilotinib—Headache—Mesalazine—Crohn's disease	0.000265	0.000776	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—Crohn's disease	0.000258	0.000757	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—Crohn's disease	0.000254	0.000745	CcSEcCtD
Nilotinib—Anaemia—Prednisone—Crohn's disease	0.000253	0.000743	CcSEcCtD
Nilotinib—Nausea—Mesalazine—Crohn's disease	0.000251	0.000736	CcSEcCtD
Nilotinib—Malaise—Prednisone—Crohn's disease	0.000247	0.000725	CcSEcCtD
Nilotinib—Vertigo—Prednisone—Crohn's disease	0.000246	0.000722	CcSEcCtD
Nilotinib—Syncope—Prednisone—Crohn's disease	0.000246	0.00072	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—Crohn's disease	0.000241	0.000706	CcSEcCtD
Nilotinib—Hypertension—Prednisone—Crohn's disease	0.000237	0.000694	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—Crohn's disease	0.000233	0.000684	CcSEcCtD
Nilotinib—Myalgia—Prednisone—Crohn's disease	0.000233	0.000684	CcSEcCtD
Nilotinib—Anxiety—Prednisone—Crohn's disease	0.000233	0.000682	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000232	0.000679	CcSEcCtD
Nilotinib—Discomfort—Prednisone—Crohn's disease	0.000231	0.000676	CcSEcCtD
Nilotinib—Oedema—Prednisone—Crohn's disease	0.000224	0.000656	CcSEcCtD
Nilotinib—Infection—Prednisone—Crohn's disease	0.000222	0.000651	CcSEcCtD
Nilotinib—Shock—Prednisone—Crohn's disease	0.00022	0.000645	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—Crohn's disease	0.00022	0.000643	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—Crohn's disease	0.000218	0.00064	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—Crohn's disease	0.000217	0.000637	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—Crohn's disease	0.000216	0.000634	CcSEcCtD
Nilotinib—Anorexia—Prednisone—Crohn's disease	0.000213	0.000625	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000204	0.000597	CcSEcCtD
Nilotinib—Insomnia—Prednisone—Crohn's disease	0.000202	0.000593	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—Crohn's disease	0.000201	0.000589	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—Crohn's disease	0.000197	0.000577	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—Crohn's disease	0.000195	0.00057	CcSEcCtD
Nilotinib—Fatigue—Prednisone—Crohn's disease	0.000193	0.000565	CcSEcCtD
Nilotinib—Constipation—Prednisone—Crohn's disease	0.000191	0.000561	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—Crohn's disease	0.000184	0.00054	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—Crohn's disease	0.000183	0.000536	CcSEcCtD
Nilotinib—Urticaria—Prednisone—Crohn's disease	0.000178	0.000521	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—Crohn's disease	0.000177	0.000518	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—Crohn's disease	0.000177	0.000518	CcSEcCtD
Nilotinib—ABCB1—lymph node—Crohn's disease	0.000167	0.000679	CbGeAlD
Nilotinib—Hypersensitivity—Prednisone—Crohn's disease	0.000165	0.000483	CcSEcCtD
Nilotinib—Asthenia—Prednisone—Crohn's disease	0.000161	0.00047	CcSEcCtD
Nilotinib—Pruritus—Prednisone—Crohn's disease	0.000158	0.000464	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—Crohn's disease	0.000153	0.000449	CcSEcCtD
Nilotinib—Dizziness—Prednisone—Crohn's disease	0.000148	0.000434	CcSEcCtD
Nilotinib—Vomiting—Prednisone—Crohn's disease	0.000142	0.000417	CcSEcCtD
Nilotinib—Rash—Prednisone—Crohn's disease	0.000141	0.000413	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—Crohn's disease	0.000141	0.000413	CcSEcCtD
Nilotinib—Headache—Prednisone—Crohn's disease	0.00014	0.000411	CcSEcCtD
Nilotinib—Nausea—Prednisone—Crohn's disease	0.000133	0.000389	CcSEcCtD
Nilotinib—PDGFRA—Signaling Pathways—SOCS1—Crohn's disease	1.68e-05	4.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RBX1—Crohn's disease	1.67e-05	4.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RASGRP1—Crohn's disease	1.67e-05	4.09e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—Crohn's disease	1.67e-05	4.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—STAT3—Crohn's disease	1.67e-05	4.08e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—STAT3—Crohn's disease	1.66e-05	4.07e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—TLR4—Crohn's disease	1.66e-05	4.06e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TLR4—Crohn's disease	1.65e-05	4.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RIPK2—Crohn's disease	1.64e-05	4.02e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—Crohn's disease	1.64e-05	4.02e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX4—Crohn's disease	1.64e-05	4.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CRP—Crohn's disease	1.64e-05	4.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—JAK2—Crohn's disease	1.64e-05	4e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RASGRP1—Crohn's disease	1.64e-05	4e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—IL6—Crohn's disease	1.63e-05	3.99e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTGER4—Crohn's disease	1.63e-05	3.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ICAM1—Crohn's disease	1.62e-05	3.97e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—ALB—Crohn's disease	1.61e-05	3.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IFNG—Crohn's disease	1.61e-05	3.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL3—Crohn's disease	1.6e-05	3.92e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—Crohn's disease	1.6e-05	3.92e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ICAM1—Crohn's disease	1.59e-05	3.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GCKR—Crohn's disease	1.59e-05	3.88e-05	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL6—Crohn's disease	1.58e-05	3.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ICAM1—Crohn's disease	1.58e-05	3.87e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—Crohn's disease	1.58e-05	3.86e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2RA—Crohn's disease	1.57e-05	3.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TLR4—Crohn's disease	1.57e-05	3.84e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TYK2—Crohn's disease	1.57e-05	3.84e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2RA—Crohn's disease	1.56e-05	3.81e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—IL6—Crohn's disease	1.56e-05	3.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—Crohn's disease	1.55e-05	3.79e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RASGRP1—Crohn's disease	1.55e-05	3.79e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—TYK2—Crohn's disease	1.55e-05	3.78e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—STAT3—Crohn's disease	1.54e-05	3.76e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SMAD3—Crohn's disease	1.53e-05	3.75e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—FADS1—Crohn's disease	1.53e-05	3.74e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—Crohn's disease	1.52e-05	3.72e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—Crohn's disease	1.51e-05	3.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SOCS1—Crohn's disease	1.51e-05	3.7e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—STAT3—Crohn's disease	1.51e-05	3.69e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—STAT3—Crohn's disease	1.51e-05	3.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ICAM1—Crohn's disease	1.51e-05	3.69e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—STAT3—Crohn's disease	1.5e-05	3.68e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2RA—Crohn's disease	1.5e-05	3.68e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SMAD3—Crohn's disease	1.5e-05	3.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—JAK2—Crohn's disease	1.5e-05	3.66e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SOCS1—Crohn's disease	1.48e-05	3.63e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—JAK2—Crohn's disease	1.47e-05	3.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—UBE2D1—Crohn's disease	1.47e-05	3.59e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—TYK2—Crohn's disease	1.46e-05	3.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SMAD3—Crohn's disease	1.45e-05	3.55e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNG—Crohn's disease	1.45e-05	3.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—Crohn's disease	1.44e-05	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—Crohn's disease	1.44e-05	3.52e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—FADS1—Crohn's disease	1.44e-05	3.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—Crohn's disease	1.43e-05	3.5e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX4—Crohn's disease	1.43e-05	3.5e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TYK2—Crohn's disease	1.43e-05	3.49e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—FADS1—Crohn's disease	1.43e-05	3.49e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RIPK2—Crohn's disease	1.42e-05	3.48e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.42e-05	3.48e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2RA—Crohn's disease	1.42e-05	3.47e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—Crohn's disease	1.42e-05	3.47e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—Crohn's disease	1.42e-05	3.47e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—Crohn's disease	1.41e-05	3.45e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—Crohn's disease	1.41e-05	3.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SOCS1—Crohn's disease	1.4e-05	3.44e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—Crohn's disease	1.4e-05	3.42e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.4e-05	3.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—JAK2—Crohn's disease	1.4e-05	3.42e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TYK2—Crohn's disease	1.39e-05	3.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL3—Crohn's disease	1.39e-05	3.39e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GCKR—Crohn's disease	1.38e-05	3.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNG—Crohn's disease	1.37e-05	3.35e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—JAK2—Crohn's disease	1.36e-05	3.33e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TLR4—Crohn's disease	1.36e-05	3.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TYK2—Crohn's disease	1.35e-05	3.31e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX4—Crohn's disease	1.35e-05	3.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2RA—Crohn's disease	1.34e-05	3.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RASGRP1—Crohn's disease	1.34e-05	3.28e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX4—Crohn's disease	1.34e-05	3.27e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—JAK2—Crohn's disease	1.33e-05	3.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—Crohn's disease	1.32e-05	3.24e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TYK2—Crohn's disease	1.32e-05	3.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TYK2—Crohn's disease	1.32e-05	3.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SMAD3—Crohn's disease	1.31e-05	3.2e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ICAM1—Crohn's disease	1.3e-05	3.19e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GCKR—Crohn's disease	1.3e-05	3.19e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—Crohn's disease	1.3e-05	3.18e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—Crohn's disease	1.29e-05	3.16e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—Crohn's disease	1.29e-05	3.16e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—TYK2—Crohn's disease	1.29e-05	3.16e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GCKR—Crohn's disease	1.29e-05	3.16e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—JAK2—Crohn's disease	1.29e-05	3.15e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TYK2—Crohn's disease	1.28e-05	3.14e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—Crohn's disease	1.28e-05	3.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SMAD3—Crohn's disease	1.28e-05	3.13e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—JAK2—Crohn's disease	1.26e-05	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—JAK2—Crohn's disease	1.26e-05	3.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—Crohn's disease	1.23e-05	3.02e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—JAK2—Crohn's disease	1.23e-05	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—Crohn's disease	1.23e-05	3.01e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—Crohn's disease	1.23e-05	3e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—JAK2—Crohn's disease	1.23e-05	3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TYK2—Crohn's disease	1.22e-05	2.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—Crohn's disease	1.22e-05	2.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—Crohn's disease	1.22e-05	2.99e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—Crohn's disease	1.22e-05	2.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TYK2—Crohn's disease	1.22e-05	2.98e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SOCS1—Crohn's disease	1.21e-05	2.97e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—Crohn's disease	1.21e-05	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SMAD3—Crohn's disease	1.21e-05	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—Crohn's disease	1.21e-05	2.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	1.21e-05	2.96e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—Crohn's disease	1.21e-05	2.96e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.21e-05	2.96e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—Crohn's disease	1.2e-05	2.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—Crohn's disease	1.2e-05	2.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—Crohn's disease	1.19e-05	2.92e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2RA—Crohn's disease	1.18e-05	2.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JAK2—Crohn's disease	1.17e-05	2.86e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—Crohn's disease	1.17e-05	2.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—Crohn's disease	1.16e-05	2.85e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—Crohn's disease	1.16e-05	2.84e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—Crohn's disease	1.16e-05	2.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—JAK2—Crohn's disease	1.16e-05	2.84e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—Crohn's disease	1.15e-05	2.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—Crohn's disease	1.15e-05	2.8e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.13e-05	2.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2RA—Crohn's disease	1.12e-05	2.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TYK2—Crohn's disease	1.11e-05	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—Crohn's disease	1.11e-05	2.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—Crohn's disease	1.11e-05	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—Crohn's disease	1.1e-05	2.7e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—Crohn's disease	1.1e-05	2.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TYK2—Crohn's disease	1.1e-05	2.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—Crohn's disease	1.1e-05	2.69e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—Crohn's disease	1.09e-05	2.67e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—Crohn's disease	1.08e-05	2.65e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—Crohn's disease	1.08e-05	2.65e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—Crohn's disease	1.08e-05	2.64e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—Crohn's disease	1.08e-05	2.64e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—Crohn's disease	1.07e-05	2.63e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—Crohn's disease	1.07e-05	2.62e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—Crohn's disease	1.06e-05	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JAK2—Crohn's disease	1.06e-05	2.59e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—Crohn's disease	1.05e-05	2.58e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—Crohn's disease	1.05e-05	2.58e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—Crohn's disease	1.05e-05	2.57e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SMAD3—Crohn's disease	1.05e-05	2.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JAK2—Crohn's disease	1.05e-05	2.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—Crohn's disease	1.03e-05	2.51e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—Crohn's disease	1.02e-05	2.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—Crohn's disease	1.02e-05	2.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—JAK2—Crohn's disease	1.01e-05	2.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—Crohn's disease	1e-05	2.45e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—Crohn's disease	9.99e-06	2.45e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	9.91e-06	2.43e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—Crohn's disease	9.91e-06	2.42e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—Crohn's disease	9.77e-06	2.39e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—Crohn's disease	9.74e-06	2.38e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2RA—Crohn's disease	9.71e-06	2.38e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—Crohn's disease	9.65e-06	2.36e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—Crohn's disease	9.58e-06	2.35e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—Crohn's disease	9.57e-06	2.34e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—Crohn's disease	9.56e-06	2.34e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JAK2—Crohn's disease	9.54e-06	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—Crohn's disease	9.46e-06	2.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—Crohn's disease	9.46e-06	2.32e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FADS1—Crohn's disease	9.41e-06	2.3e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	9.39e-06	2.3e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—JAK2—Crohn's disease	9.32e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—Crohn's disease	9.26e-06	2.27e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—Crohn's disease	9.23e-06	2.26e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	9.22e-06	2.26e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—Crohn's disease	9.04e-06	2.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JAK2—Crohn's disease	9.03e-06	2.21e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—Crohn's disease	9e-06	2.2e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—Crohn's disease	8.88e-06	2.17e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—Crohn's disease	8.84e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—Crohn's disease	8.83e-06	2.16e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX4—Crohn's disease	8.81e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—Crohn's disease	8.77e-06	2.15e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—Crohn's disease	8.7e-06	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—Crohn's disease	8.57e-06	2.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	8.52e-06	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—Crohn's disease	8.52e-06	2.09e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCKR—Crohn's disease	8.51e-06	2.08e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—Crohn's disease	8.39e-06	2.05e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—Crohn's disease	8.39e-06	2.05e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—Crohn's disease	8.35e-06	2.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—Crohn's disease	8.24e-06	2.02e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—Crohn's disease	8.13e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	8.13e-06	1.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	8.07e-06	1.97e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JAK2—Crohn's disease	7.96e-06	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—Crohn's disease	7.91e-06	1.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—Crohn's disease	7.76e-06	1.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—Crohn's disease	7.69e-06	1.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—Crohn's disease	7.67e-06	1.88e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—Crohn's disease	7.56e-06	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JAK2—Crohn's disease	7.55e-06	1.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	7.42e-06	1.82e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—Crohn's disease	7.41e-06	1.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—Crohn's disease	7.27e-06	1.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—Crohn's disease	7.16e-06	1.75e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—Crohn's disease	7.12e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—Crohn's disease	7e-06	1.71e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—Crohn's disease	6.98e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—Crohn's disease	6.89e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—Crohn's disease	6.84e-06	1.67e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—Crohn's disease	6.84e-06	1.67e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—Crohn's disease	6.8e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—Crohn's disease	6.63e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—Crohn's disease	6.61e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JAK2—Crohn's disease	6.53e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—Crohn's disease	6.47e-06	1.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—Crohn's disease	6.45e-06	1.58e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—Crohn's disease	6.31e-06	1.55e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—Crohn's disease	6.28e-06	1.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—Crohn's disease	5.99e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	5.97e-06	1.46e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—Crohn's disease	5.96e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—Crohn's disease	5.96e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—Crohn's disease	5.95e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—Crohn's disease	5.84e-06	1.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—Crohn's disease	5.54e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—Crohn's disease	5.42e-06	1.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—Crohn's disease	5.37e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—Crohn's disease	5.22e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—Crohn's disease	5.17e-06	1.27e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—Crohn's disease	5.05e-06	1.24e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—Crohn's disease	4.89e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—Crohn's disease	4.79e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—Crohn's disease	4.78e-06	1.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—Crohn's disease	4.63e-06	1.13e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—Crohn's disease	4.42e-06	1.08e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—Crohn's disease	4.4e-06	1.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	4.17e-06	1.02e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—Crohn's disease	4.14e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—Crohn's disease	4.11e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—Crohn's disease	4.08e-06	9.99e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—Crohn's disease	3.87e-06	9.47e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—Crohn's disease	3.85e-06	9.41e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—Crohn's disease	3.62e-06	8.87e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—Crohn's disease	3.59e-06	8.8e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—Crohn's disease	3.35e-06	8.19e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—Crohn's disease	2.71e-06	6.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	2.37e-06	5.8e-06	CbGpPWpGaD
